Compositions and methods for treating retroviral infections

• US 7,157,083 B2
• Filed: 01/16/2002
• Issued: 01/02/2007
• Est. Priority Date: 04/17/1998
• Status: Expired due to Fees

• Current Assignee: Surrogate Pharmaceutical Pathways
• Original Assignee: Surrogate Pharmaceutical Pathways, LLC
• Inventors: Gallina, Damian J.
• Primary Examiner(s): Tate; Christopher
• Assistant Examiner(s): WINSTON, RANDALL O
• Application Number:
  US10/050,655
• Publication Number:
  US 20020164321A1
• Time in Patent Office: 1,812 Days
• Field of Search: 424/96.62, 424/208.1, 424/94.1, 424/94.61
• US Class Current: 424/94.61
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5158 Antigen-pulsed cells, e.g. T-cells
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/21 Retroviridae, e.g. equine infectious anemia virus
• CPC Class Codes: A61K 39/4614 Monocytes; Macrophages
• CPC Class Codes: A61K 39/4622 Antigen presenting cells
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: C12N 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2740/16061 Methods of inactivation or attenuation
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention relates to hyaluronidase enzyme methods, vaccines and compositions for treating or preventing pathogenic infections, such as HIV, in a patient. The invention also relates to methods, vaccines and compositions for providing immunity against HIV infection in a patient comprising treating the patient with HIV virus or HIV infected cells that have been treated with hyaluronidase.

Claims

1. A composition comprising:

a) HIV infected cells that have been treated with a bovine hyaluronidase or a hyaluronidase enzyme with comparable activity at a concentration of at least 0.01611 units/mL, and

b) optionally a pharmaceutically acceptable carrier or diluent.

2. The composition of claim 1 wherein the HIV infected cells are human host cells.

3. The composition of claim 2 wherein the HIV infected cells are human peripheral blood mononuclear cells or antigen presenting cells.

4. The composition of claim 2 wherein the HIV infected cells exhibit reduced cell viability.

5. The composition of claim 4 wherein the HIV infected cells form HIV immunogens.

6. The composition of claim 5 wherein the immunogens prime and activate antigen presenting cells.

7. The composition of claim 6 wherein the antigen presenting cells are macrophages, monocytes or both.

8. The composition of claim 7 wherein the antigen presenting cells are capable of engendering an immune response that imparts to naï

ve cells resistance to HIV challenge.

9. The composition of claim 7 wherein the antigen presenting cells are capable of transferring HIV immunity to naï

ve cells following co-incubation with the treated cells.